As glucocorticoids and immunosuppressive drugs are non‐specific therapeutic agents that
cause many adverse reactions, the development of biologicals aiming to control specific …

With the approval by the FDA in 2011 of a biologic agent (namely belimumab) for the
treatment of systemic lupus erythematosus (SLE), optimism abounds that additional biologic …

Background Baricitinib is an oral selective inhibitor of Janus kinase 1 and 2 approved for the
treatment of rheumatoid arthritis, atopic dermatitis, and alopecia areata. In a 24-week phase …

Background Baricitinib is an oral selective inhibitor of Janus kinase 1 and 2 approved for the
treatment of rheumatoid arthritis, atopic dermatitis, and alopecia areata. In a 24-week phase …

B cell hyperactivity and breach of tolerance constitute hallmarks of systemic lupus
erythematosus (SLE). The heterogeneity of disease manifestations and relatively rare …

Systemic lupus erythematosus (SLE) is a complex autoimmune disease with substantial
clinical heterogeneity. Current treatments for SLE are effective at reducing morbidity and …

Systemic lupus erythematosus (SLE) is a chronic autoimmune inflammatory disease
affecting multiple organ systems that runs an unpredictable course and may present with a …

Background Patients with systemic lupus erythematosus have substantial unmet medical
need. Baricitinib is an oral selective Janus kinase (JAK) 1 and JAK2 inhibitor that we …

Systemic lupus erythematosus (SLE) is a prototypic autoimmune disease characterized by
impaired immune tolerance, resulting in the generation of pathogenic autoantibodies and …

Systemic lupus erythematosus (SLE, lupus) is a highly complex and heterogeneous
autoimmune disease that most often afflicts women in their child-bearing years. It is …